Recent Updates
Recently added Catalysts
NSRX Negative Sentiment Score: 20/100

NASUS PHARMA LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 UNAUDITED U.S DOLLARS IN THOUSANDS INDEX Unaudited Interim Condensed Balance Sheets F-2 Unaudited Interim Condensed Statements of Operations F-3 Unaudi

Monday, December 29, 2025 1 min read
Key Takeaway: Nasus Pharma Ltd. has released its condensed financial statements as of June 30, 2025, which remain unaudited. The document includes interim balance sheets and statements of operations, although it does not provide detailed financial performance metrics. This lack of audited verification and comprehensive data may create uncertainty regarding the company's financial health and operating results.

Market Sentiment Analysis

CONCERNS & RISKS

  • The financial statements are presented as unaudited, which may raise concerns about their reliability.
  • Lack of detailed financial performance data limits investors' understanding of the company's current position.

Full Press Release Details

us-gaap:RelatedPartyMember
us-gaap:RelatedPartyMember
us-gaap:RelatedPartyMember
us-gaap:RelatedPartyMember
us-gaap:CommonStockMember
us-gaap:AdditionalPaidInCapitalMember
us-gaap:RetainedEarningsMember
us-gaap:CommonStockMember
us-gaap:AdditionalPaidInCapitalMember
us-gaap:RetainedEarningsMember
us-gaap:CommonStockMember
us-gaap:AdditionalPaidInCapitalMember
us-gaap:RetainedEarningsMember
us-gaap:CommonStockMember
us-gaap:AdditionalPaidInCapitalMember
us-gaap:RetainedEarningsMember
us-gaap:CommonStockMember
us-gaap:AdditionalPaidInCapitalMember
us-gaap:RetainedEarningsMember
us-gaap:CommonStockMember
us-gaap:AdditionalPaidInCapitalMember
us-gaap:RetainedEarningsMember
us-gaap:SubsequentEventMember
us-gaap:OverAllotmentOptionMember
us-gaap:OverAllotmentOptionMember
NSRX:RonnieHershmanAndMichaelGibberMember
NSRX:RonnieHershmanAndMichaelGibberMember
NSRX:DrRonnnieHershmanMember
NSRX:MichaelGibberMember
NSRX:MrUdiGilboaMember
NSRX:DrDaliaMegiddoMember
NSRX:DrRonnieHershmanMember
us-gaap:InvestorMember
us-gaap:CommonStockMember
us-gaap:SubsequentEventMember
NSRX:WeightAverageCostCapitalMember
NSRX:WeightAverageCostCapitalMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
us-gaap:MeasurementInputExpectedTermMember
us-gaap:MeasurementInputExpectedTermMember
us-gaap:MeasurementInputExpectedTermMember
us-gaap:MeasurementInputExpectedTermMember
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueInputsLevel1Member
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueInputsLevel3Member
NSRX:LicenseAgreementMember
NSRX:LicenseAgreementMember
NSRX:ServiceAgreementMember
NSRX:ServiceAgreementMember
NSRX:ServiceAgreementMember
NSRX:ServiceAgreementMember
NSRX:NonRecurringResearchArrangementMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalNaloxonePowderSprayMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalNaloxonePowderSprayMember
NSRX:DevelopmentStageMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalNaloxonePowderSprayMember
NSRX:NewDrugApplicationMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalNaloxonePowderSprayMember
NSRX:MarketLaunchMember
NSRX:ServiceAgreementMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalNaloxonePowderSprayMember
NSRX:ServiceAgreementMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalEpinephrinePowderCandidateMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalEpinephrinePowderCandidateMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalEpinephrinePowderCandidateMember
NSRX:DevelopmentStageMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalEpinephrinePowderCandidateMember
NSRX:NewDrugApplicationMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalEpinephrinePowderCandidateMember
NSRX:MarketLaunchMember
NSRX:ServiceAgreementMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalEpinephrinePowderCandidateMember
NSRX:AptarTechnologyMember
NSRX:AptarTechnologyMember
NSRX:NasusPharmasIntranasalNaloxonePowderSprayMember
NSRX:NasusPharmasIntranasalEpinephrinePowderCandidateMember
NSRX:ShareOptionsMember
NSRX:ShareOptionsMember
NSRX:TwoThousandTwentyTwoSimpleAgreementsFutureEquityMember
NSRX:TwoThousandTwentyTwoSimpleAgreementsFutureEquityMember
NSRX:TwoThousandTwentyThreeSimpleAgreementsFutureEquityMember
NSRX:TwoThousandTwentyThreeSimpleAgreementsFutureEquityMember
NSRX:TwoThousandTwentyFourSimpleAgreementsFutureEquityMember

Frequently Asked Questions

What is a RelatedPartyMember?

A RelatedPartyMember refers to individuals or entities connected through financial ties.

What are the components of Common Stock?

Common Stock includes shares of ownership in a company granted to investors.

What does Retained Earnings represent?

Retained Earnings indicate the accumulated net income retained for reinvestment.

What is a License Agreement in biopharma?

A License Agreement allows one party to use another's intellectual property rights.

What does Development Stage mean in biopharma?

Development Stage signifies the phase of research and testing before market launch.

Tags: NSRX Viatris Investor Conferences Healthcare Nasus Pharma unaudited financials Q2 2025 financial statements
Last updated: Dec 29, 2025